PDF(Pubmed)
Abstract：
Acinetobacter baumannii represents a significant concern in nosocomial settings, particularly in critically ill patients who are forced to remain in hospital for extended periods. The challenge of managing and preventing this organism is further compounded by its increasing ability to develop resistance due to its extraordinary genomic plasticity, particularly in response to adverse environmental conditions. Its recognition as a significant public health risk has provided a significant impetus for the identification of new therapeutic approaches and infection control strategies. Indeed, currently used antimicrobial agents are gradually losing their efficacy, neutralized by newer and newer mechanisms of bacterial resistance, especially to carbapenem antibiotics. A deep understanding of the underlying molecular mechanisms is urgently needed to shed light on the properties that allow A. baumannii enormous resilience against standard therapies. Among the most promising alternatives under investigation are the combination sulbactam/durlobactam, cefepime/zidebactam, imipenem/funobactam, xeruborbactam, and the newest molecules such as novel polymyxins or zosurabalpin. Furthermore, the potential of phage therapy, as well as deep learning and artificial intelligence, offer a complementary approach that could be particularly useful in cases where traditional strategies fail. The fight against A. baumannii is not confined to the microcosm of microbiological research or hospital wards; instead, it is a broader public health dilemma that demands a coordinated, global response.
摘要：
鲍曼不动杆菌是医院环境中的一个重要问题，特别是那些被迫长期住院的危重病人。由于其非凡的基因组可塑性，其产生抗性的能力不断增强，进一步加剧了管理和预防这种生物的挑战。特别是在应对不利的环境条件。它被认为是重大的公共卫生风险，为确定新的治疗方法和感染控制策略提供了重要动力。的确,目前使用的抗菌剂正逐渐失去其功效，被越来越新的细菌抗性机制中和，尤其是碳青霉烯类抗生素。迫切需要对潜在的分子机制进行深入的了解，以揭示鲍曼不动杆菌对标准疗法具有巨大弹性的特性。正在研究中的最有希望的替代品是舒巴坦/杜洛巴坦的组合，头孢吡肟/齐达巴坦,亚胺培南/funobactam，xeruborbactam,和最新的分子，如新型多粘菌素或zosurabalpin。此外，噬菌体疗法的潜力，以及深度学习和人工智能，提供一种互补的方法，在传统策略失败的情况下特别有用。与鲍曼不动杆菌的斗争不仅限于微生物学研究或医院病房的缩影；相反，这是一个更广泛的公共卫生困境，需要协调，全球反应。
